NCT06887322View on ClinicalTrials.gov

The Efficacy of Topical Formulation Containing Ciplukan (Physalis Angulata Linn.) on Psoriasis Vulgaris Lesions

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 13, 2025

Primary Completion Date

April 10, 2025

Study Completion Date

April 10, 2025

Conditions
Psoriasis VulgarisInflammation
Interventions
DRUG

Ciplukan

A minimum amount of 20 psoriasis vulgaris lesion treated with the topical formulation containing 20% ciplukan (Physalis angulata Linn.) extract, applied twice a day for 14 days.

DRUG

Bethametasone valerate 0,1% cream

A minimum amount of 20 psoriasis vulgaris lesion treated with the bethametasone valerate 0,1% cream, applied twice daily for 14 days.

Trial Locations (1)

40161

Hasan Sadikin General Hospital, Bandung

All Listed Sponsors
lead

Universitas Padjadjaran

OTHER